On Tuesday, OHR Pharmaceutical Inc (NASDAQ:OHRP)’s shares declined -4.80% to $3.17.
Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, recently declared positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO). The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis(R) achieved greater visual acuity gains than the control group who received Lucentis alone. At week 38, the mean gain in visual acuity from baseline for patients randomized (at week 10) to treatment with OHR-102 + Lucentis PRN was +27.8 letters contrast with +23.3 for patients randomized to treatment with Lucentis plus PRN alone (control group), a clinically meaningful difference of +4.5 letters. The data were presented by John Wroblewski, MD, a retina specialist at Cumberland Valley Retina Consultants on Saturday, July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists (ASRS) in Vienna, Austria.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
Health Care REIT, Inc. (NYSE:HCN)’s shares dropped -0.36% to $67.10.
Health Care REIT, Inc. (HCN) recently declared that it is notifying holders of its 3.00% Convertible Senior Notes due 2029 (the “Notes”) that the company will redeem all outstanding Notes ($22,415,000 aggregate principal amount as of July 17, 2015, which amount does not comprise Notes surrendered for conversion preceding to July 17, 2015) on August 17, 2015 at a price payable in cash equal to 100% of the principal amount of the Notes being redeemed, plus accrued and unpaid interest through and counting August 16, 2015 (the “Redemption Price”).
The company also declared recently that it is notifying holders of the Notes that they are entitled to convert all or a portion of their Notes into cash and, if applicable, shares of the company’s common stock (the “Conversion Option”). Holders’ right to convert starts on July 17, 2015 and ends at the close of business on August 14, 2015, unless there is a default in the payment of the Redemption Price or accrued and unpaid interest. The Notes are convertible because the company has called the Notes for redemption.
Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The firm primarily invests in senior living and health care properties.
At the end of Tuesday’s trade, First Niagara Financial Group Inc. (NASDAQ:FNFG)‘s shares dipped -0.73% to $9.50.
First Niagara Financial Group, Inc. (FNFG) named Jeff L. Hubbard to serve as New England Regional President, leading the company’s New Haven-based team of bankers across Connecticut and Massachusetts.
Hubbard joins First Niagara from TD Bank, N.A., where he served for six years, most recently as Regional Vice President, Commercial Banking responsible for managing the daily business activities for the bank in the Hartford region of Connecticut, in addition to expanded responsibility for leading the bank’s commercial, middle market and small business lending activities statewide.
First Niagara Financial Group, Inc. operates as the bank holding company for First Niagara Bank, N.A. that provides retail and commercial banking, and other financial services to individuals, families, and businesses.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), ended its Tuesday’s trading session with 0.90% gain, and closed at $56.18.
ISIS Pharmaceuticals, Inc. (ISIS) offered an update on children with spinal muscular atrophy (SMA) who have accomplished the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are ongoing to receive treatment in an open-label extension (OLE) study. Comprising with earlier observations, enhances in muscle function scores and additional motor function tests were observed in children treated with ISIS-SMNRx. Isis is presently collaborating with Biogen to develop and commercialize ISIS-SMNRx to treat patients with SMA.
In the OLE study, a total of 30 children with Type II or Type III SMA received 12 mg of ISIS-SMNRx dosed intrathecally every six months. Children who enrolled in the OLE study had accomplished the open-label Phase 2 study of ISIS-SMNRx in which they had received multiple doses of either 3 mg, 6 mg, 9 mg, or 12 mg of ISIS-SMNRx. Clinical endpoints were measured every three months and contrast to each patient’s Phase 2 baseline score. These endpoints comprised of measurements of muscle function using the Hammersmith Functional Motor Scale-Expanded (HFMSE), the six minute walk test (6MWT) for ambulatory patients and the upper limb module (ULM) test for non-ambulatory patients.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
